# A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(U.S. and German Sourced) in Healthy Chinese Male Subjects

> **NCT02581748** · PHASE1 · COMPLETED · sponsor: **Shanghai Henlius Biotech** · enrollment: 123 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HLX02
- **DRUG:** Herceptin

## Key facts

- **NCT ID:** NCT02581748
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-16
- **Primary completion:** 2016-05-11
- **Final completion:** 2017-01-25
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2022-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02581748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02581748, "A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(U.S. and German Sourced) in Healthy Chinese Male Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02581748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*